

## ***Request under Freedom of Information Act 2000***

Thank you for your request for information which we received on 13 October 2022.

I am pleased to confirm the following.

**Q1. In the past 3 months, how many Lung patients were treated with: We are not able to access other databases than the SACT prescribing system to obtain this data. Therefore, please find information for all patients with lung cancer**

- Afatinib 4
- Alectinib-1
- Amivantamab -0
- Atezolizumab monotherapy
- Atezolizumab with chemotherapy- 4
- Brigatinib-0
- Ceritinib -1
- Crizotinib -0
- Dacomitinib-0
- Dabrafenib with Trametinib-0
- Durvalumab-2
- Erlotinib-0
- Gefitinib-0
- Lorlatinib-1
- Mobocertinib-0
- Nintedanib with Docetaxel-2
- Nivolumab- 0
- Osimertinib -6
- Pembrolizumab monotherapy-9
- Pembrolizumab with chemotherapy- 13
- Pemetrexed with Carboplatin/Cisplatin- 3
- Pralsetinib-0
- Selpercatinib-0
- Sotorasib-0
- Tepotinib-0
- Vinorelbine with Carboplatin/Cisplatin-2
- Any other active systemic anti-cancer therapy (SACT)- Gemcitabine single agent - 2

Gemcitabine Cisplatin- 1 Carboplatin Paclitaxel Pembrolizumab - 2 , vinorelbine single agent oral - 1, Pemetrexed monotherapy - 1, Carboplatin Etoposide-1

- Palliative care only- no conclusive information

**Q2. In the past 3 months, how many patients were treated for Squamous non-small cell lung cancer (Sq NSCLC) ONLY with the following drugs:**

- Atezolizumab monotherapy
- Atezolizumab with chemotherapy
- Durvalumab
- Nivolumab
- Osimertinib
- Pembrolizumab (Keytruda) Mono
- Pembrolizumab (Keytruda) with Chemotherapy
- Tepotinib
- Other active systemic anti-cancer therapy (SACT)
- Palliative care only

This is exempt under section 40 – personal information – this would involve searching through patient medical records.

**Q3. Do you participate in any clinical trials for non-small cell lung cancer (NSCLC)? If so, could you please provide the name of each trial and the number of patients taking part.**

No, we are not currently open to any NSCLC trials.

You are advised that this information is provided in accordance with the Freedom of Information Act 2000 and is for your personal use. Any re-use of this information will be subject to copyright and the Re-Use of Public Sector Information Regulations (1st July 05) and authorisation from Milton Keynes Hospital NHS Foundation Trust will be required. In the event of any re-use, the information must be reproduced accurately and not used in a misleading manner.

If you are unhappy with the information received in response to this request, please address your complaint to the Patient Affairs Office at Milton Keynes Hospital NHS Foundation Trust, Standing Way, Eaglestone, Milton Keynes MK6 5LD. If, after exhausting our internal process, you are still unhappy with the information received, you may write to the Information Commissioner's Office, Wycliffe House, Water Lane, Wilmslow, Cheshire SK9 5AF.

If you need any further assistance, please do not hesitate to contact us at the address above.

Yours sincerely,

Freedom of Information Co-ordinator  
For and on behalf of Milton Keynes Hospital NHS Foundation Trust

Any re-use of this information will be subject to the 'Re-use of Public Sector Information Regulations' and best practice.
---